Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 16, 2008

OmegaGenesis to Leverage Mayo Clinic’s Nanomaterial Research in Angiogenesis Applications

  • OmegaGenesis and Mayo Clinic have decided to work together to discover and validate nanomaterials in angiogenesis applications. The deal includes licenses for Mayo Clinic technology and patents as well as a research collaboration.

    The firm will leverage Mayo Clinic researchers’ work in which they produced a rare earth material in nano size and established nontoxicity of the material for human applications. Additionally, they have shown that the material induces endothelial cell growth and produces new blood vessels. 

    OmegaGenesis has the exclusive rights to further test angiogenesis characteristics of the nano rods developed at Mayo Clinic. The company will support ongoing research projects in early-development stages at the Clinic, and the organizations will together conduct lab tests.

    “Our goal is to supplement natural human body management and re-enable where some natural processes have stopped or diminished,” comments  Oostur Raza, president and CEO of OmegaGenesis.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »